Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index

Kim M. Summers, June W. Halliday, Lawrie W. Powell – 1 July 1990 – The value of measurement of hepatic iron concentration and determination of the hepatic iron index in distinguishing homozygotes from heterozygotes for hemochromatosis was examined. The study group included 42 homozygotes with an unequivocal diagnosis of hemochromatosis and six individuals who had initial equivocal results but were established as homozygous after extensive follow‐up.

Binding of the major and large HBsAg to human hepatocytes and liver plasma membranes: Putative external and internal receptors for infection and secretion of hepatitis B virus

William P. J. Leenders, Harrie L. Glansbeek, Wieke C. C. De Bruin, Sing‐Hiem Yap – 1 July 1990 – A likely mechanism of the strong hepatotrophism of the hepatitis B virus is the presence of specific receptors for the surface antigen of hepatitis B virus on hepatocyte membranes. To examine this hypothesis, we have performed binding studies using recombinant large (preS1 + preS2 + S) and major (S) proteins with adult human hepatocytes, rat hepatocytes, human fibroblasts, human peripheral blood mononuclear cells and plasma membranes derived from these cell types.

Physicochemical determinants in hepatic extraction of small peptides

Ellen B. Hunter, Stephen P. Powers, Louis J. Kost, Delia I. Pinon, Laurence J. Miller, Nicholas F. LaRusso – 1 July 1990 – Although the liver is known to extract amino acids and organic anions by well‐characterized transport systems, the factors that regulate the hepatic uptake of small, circulating peptides are poorly understood. We previously reported that cholecystokinin octapeptide, a biologically active form of cholecystokinin, is efficiently cleared by the liver and that uptake depends on its carboxyl‐terminal tetrapeptide (Trp‐Met‐Asp‐PheNH2).

Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture

Subhankar Bandyopadhyay, James E. Klaunig, Pitambar Somani – 1 July 1990 – Hepatocytes from adult male Sprague‐Dawley rats were isolated by the two‐stage collagenase perfusion technique; 1 × 106 cells/plate were incubated in primary cell culture in Leibovitz's L‐15 medium for 24 hr with or without various concentrations (12.5 to 400 μmol/L) of cardioactive cationic amphiphilic compounds such as propranolol, verapamil, sotalol, atenolol and procainamide.

Abnormal pressor response to vasopressin in patients with cirrhosis: Evidence for impaired buffering mechanisms

Richard Moreau, Antoine Hadengue, Thierry Soupison, Guy Mechin, Michel Assous, Jacqueline Roche‐Sicot, Christian Sicot – 1 July 1990 – In patients with cirrhosis, vasopressin infusion induces sustained vasoconstriction and elevation of arterial pressure. The vasopressor effect could be caused by impairment of mechanisms normally aimed at buffering increases in arterial pressure (reflex bradycardia and decreases in arteriolar resistance).

Histochemical and immunohistochemical evidence for hepatic zone 3 distribution of alcohol dehydrogenase in rats

Shinzo Kato, Hiromasa Ishii, Sadakazu Aiso, Shuji Yamashita, Daisuke Ito, Masaharu Tsuchiya – 1 July 1990 – The distribution of alcohol dehydrogenase in the hepatic acinus was examined by both histochemical and immunohistochemical approaches. The immunohistochemical method using anti–alcohol dehydrogenase antibody indicated zone 3 predominance of this enzyme in the hepatic acinus, whereas a conventional histochemical method showed slight zone 1 predominance.

Familial polyposis coli and hepatocellular neoplasms

H. J. R. Bussey – 1 July 1990 – Two cases of hepatocellular carcinoma in patients with familial polyposis coli (FPC) have recently been reported in the literature. Hepatoblastoma was also reported in five children with maternal ancestors with FPC. We report a case of hepatoblastoma in a female infant whose father has FPC as further evidence of an association between hepatoblastoma and FPC.

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: First controlled data

Marie Borum, Hans Fromm – 1 July 1990 – We studied the effect of ursodeoxycholic acid on 18 women and 2 men with primary biliary cirrhosis, mainly stages I and II. After a 3‐mo observation period, patients were randomized to a 9‐mo treatment period with ursodeoxycholic acid, 10 mg/kg · day, or placebo. Two patients on placebo left the study.

Subscribe to